PTCT Logo

PTC Therapeutics, Inc. (PTCT) 

NASDAQ
Market Cap
$3.27B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
193 of 776
Rank in Industry
113 of 433

Largest Insider Buys in Sector

PTCT Stock Price History Chart

PTCT Stock Performance

About PTC Therapeutics, Inc.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic …

Insider Activity of PTC Therapeutics, Inc.

Over the last 12 months, insiders at PTC Therapeutics, Inc. have bought $198,736 and sold $2.3M worth of PTC Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at PTC Therapeutics, Inc. have bought $424,214 and sold $22.4M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Gravier Pierre (CHIEF FINANCIAL OFFICER) — $198,736.

The last purchase of 7,700 shares for transaction amount of $198,736 was made by Gravier Pierre (CHIEF FINANCIAL OFFICER) on 2023‑12‑12.

List of Insider Buy and Sell Transactions, PTC Therapeutics, Inc.

2024-07-16SaleCHIEF FINANCIAL OFFICER
2,269
0.0029%
$34.02$77,200+2.40%
2024-05-22Saledirector
20,000
0.0258%
$38.24$764,800-8.29%
2024-05-07SaleEVP & CHIEF MEDICAL OFFICER
175
0.0002%
$32.82$5,744+11.10%
2024-04-19SaleCHIEF EXECUTIVE OFFICER
3,361
0.0043%
$24.89$83,669+38.41%
2024-04-17SaleCHIEF EXECUTIVE OFFICER
1,307
0.0017%
$25.14$32,851+38.96%
2024-04-17SaleCHIEF EXECUTIVE OFFICER
787
0.001%
$25.14$19,781+38.96%
2024-04-02SaleEVP & CHIEF MEDICAL OFFICER
526
0.0007%
$28.37$14,923+20.32%
2024-01-30SaleEXEC. VP AND CLO
794
0.0011%
$27.25$21,637+22.32%
2024-01-30SaleCHIEF BUSINESS OFFICER
366
0.0005%
$27.25$9,974+22.32%
2024-01-30SaleSVP, CHIEF ACCOUNTING OFFICER
318
0.0004%
$27.25$8,666+22.32%
2024-01-30SaleCHIEF TECHNICAL OPS OFFICER
646
0.0009%
$27.25$17,604+22.32%
2024-01-22Saledirector
10,000
0.0133%
$27.38$273,804+17.94%
2024-01-09SaleCHIEF EXECUTIVE OFFICER
5,443
0.0073%
$29.01$157,928+11.90%
2024-01-09SaleEXEC. VP AND CLO
1,938
0.0026%
$29.01$56,231+11.90%
2024-01-09SaleCHIEF BUSINESS OFFICER
2,065
0.0028%
$29.01$59,916+11.90%
2024-01-09SaleCHIEF MEDICAL OFFICER
1,225
0.0016%
$29.01$35,543+11.90%
2024-01-09SaleSVP, FINANCE & CAO
1,653
0.0022%
$29.01$47,961+11.90%
2024-01-09SaleCHIEF TECHNICAL OPS OFFICER
1,621
0.0022%
$29.01$47,033+11.90%
2024-01-08SaleCHIEF EXECUTIVE OFFICER
2,237
0.0029%
$28.64$64,068+7.94%
2024-01-08Saledirector
1,500
0.0019%
$27.81$41,715+7.94%

Insider Historical Profitability

20.77%
SCHMERTZLER MICHAELdirector
115266
0.1498%
$42.4952+30.17%
Gravier PierreCHIEF FINANCIAL OFFICER
53531
0.0696%
$42.4911
HBM Healthcare Investments (Cayman) Ltd.10 percent owner
2441504
3.1739%
$42.4911+8.52%
Koppel Adamdirector
2333333
3.0333%
$42.4910+8.52%
Vulcan Ventures Inc.director
803067
1.044%
$42.4910+8.52%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$272.54M12.229.37M+6.46%+$16.53M0.01
Wellington Management Company$258.95M11.618.9M-9.32%-$26.62M0.04
BlackRock$220.07M9.867.57M-0.9%-$2.01M0.01
RTW Investments, LP$215.96M9.687.42M0%+$03.24
Armistice Capital Llc$196.76M8.826.76M-1.46%-$2.91M0.63
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.